Marco's Morning Report — Sunday, June 21, 2026

Medicare's GLP-1 Bridge goes live July 1 — your Part D patients get $50/mo semaglutide & tirzepatide

After a year of false starts, CMS's Medicare GLP-1 Bridge switches on July 1, 2026 and runs through Dec 31, 2027. Eligible Part D beneficiaries pay a flat $50/month copay for covered anti-obesity GLP-1s — and notably, coverage is for the weight-loss indication alone, no separate qualifying diagnosis required. The broader BALANCE Part D model was shelved indefinitely; the Bridge is what's actually shipping. Expect a wave of newly-covered older adults starting or restarting these drugs.

Why it lands on your unit: more admitted elders will be on semaglutide/tirzepatide, which matters for med rec, NPO/aspiration risk before procedures (delayed gastric emptying), and discharge scripts patients now expect to be affordable.

Action: worth a quick huddle with pharmacy on a "hold GLP-1 before sedation/endoscopy" prompt and on flagging the new $50 pathway at discharge so patients aren't told the drug is unaffordable. CMS Bridge page · KFF explainer

Florida's July 1 health laws: PBM reform takes effect, plus a sickle-cell pain CME mandate

Among the ~90 Florida laws effective July 1 is the Drug Prices and Coverage Act (signed March 24), which tightens rules on Pharmacy Benefit Managers — barring PBMs from forcing pharmacies to dispense below cost and from steering patients to favored pharmacies, and letting in-network pharmacies file consolidated appeals. Separately, Florida now requires controlled-substance CE for licensed prescribers to include specific instruction on managing severe sickle-cell pain.

Why it matters to you: the PBM rules may smooth some discharge-pharmacy friction, and the sickle-cell content is a relevant nudge given how often pain management for SCD admissions gets second-guessed.

Action: keep the sickle-cell CE requirement in mind next time you renew controlled-substance CE — and expect your hospital pharmacy to flag workflow tweaks. Akerman 2026 FL health-law review

The DebateSection B · both sides, no verdict

Should Medicare cover GLP-1 drugs for weight loss?

Why it's live: the Medicare GLP-1 Bridge starts paying for anti-obesity GLP-1s on July 1 — the first time traditional Medicare has covered these drugs for weight loss alone, reviving a years-long fight over cost versus access just as the checks start going out.

FOR — treat obesity, save downstream

Obesity is a chronic disease, and pricing seniors out of the most effective treatment is the false economy. As AMA President Bobby Mukkamala, MD puts it, "patients should not face insurmountable financial barriers to clinically appropriate care." Supporters — the AMA, ASMBS, and diabetes-care advocates — point to GLP-1s' documented gains beyond weight: better blood pressure, lipids, and glycemic control in a population where those drive the cardiac and renal admissions you see nightly. Pair the drug with lifestyle support, they argue, and Medicare buys fewer strokes, fewer heart-failure decompensations, and fewer dialysis starts down the line.

AMA — doctors fighting for anti-obesity drug access

AGAINST — an open-ended bill nobody has priced

The math is the problem. Independent estimates put the cost of covering obesity GLP-1s in Part D at roughly $25–35 billion over a decade (some models higher), and CMS still hasn't disclosed its own projection — STAT reported the Bridge "could cost taxpayers billions" with no public number. The American Action Forum argues the coverage was engineered as an administrative end-run — set from the White House rather than through CMS's normal formulary and benefit vetting — and warns each million new users adds about $1.74 billion a year. With uncertain long-term adherence and rebound after stopping, critics ask whether a tight Medicare budget should absorb an open-ended drug tab before the savings are proven.

STAT — could cost taxpayers billions · AAF analysis

Where it lands: the Bridge is a time-limited demonstration through Dec 31, 2027 — so its real-world cost and outcomes data will become the ammunition for whether Medicare makes obesity coverage permanent.

On My RadarSection C · noteworthy, not urgent

Mets get steamrolled in Philly, 15–3. June 20 was ugly: Kyle Schwarber went 4-for-5 with six RBIs and Bryce Harper hit for the cycle (11th in Phillies history) while Cristopher Sánchez cruised. The Mets sit around 33–41 and need the cavalry. Box

Update — Lindor is close. Francisco Lindor and Tyrone Taylor both started rehab assignments with Double-A Binghamton, setting Lindor up for a return to the lineup soon — the most encouraging thread in an otherwise rough stretch. Amazin' Avenue

Update — Cuba passes its biggest economic shift since the revolution. The National Assembly approved 176 transformation measures — opening private banking, currency-exchange houses, converting state firms to commercial entities, scrapping the 100-worker cap on private business, and opening a door to private real estate. ECLAC still projects a 6.5% GDP drop in 2026. Al Jazeera · PBS

Puerto Rico's growth forecast stays flat. The Planning Board and local economists are holding a slowdown call — roughly 0% GNP growth for 2026 — with energy costs (Puerto Ricans pay nearly double mainland electric rates) and federal-policy uncertainty cited as the drag, alongside ongoing physician outflow. El Nuevo Día

For the queue: The Pitt Season 2. The ER drama's second season is drawing strong critical marks for "narrative excellence" and heart — the rare medical show clinicians don't have to grit their teeth through. Rotten Tomatoes

Trends to WatchSection D · emerging signals

Delirium prevention is shifting from "screen" to "default." The 2026 framing treats cognition, mobility, sleep, hydration, and medication safety as ordinary care for every older admission, not a consult triggered after CAM turns positive — reinforced by recent data tying polypharmacy and sedative/anticholinergic burden to delirium risk. Quietly changing what "routine" admission orders should look like. Sedative/anticholinergic burden study

GLP-1s are becoming a perioperative variable on the floor. As coverage expands (see Top Stories), more inpatients arrive on weekly GLP-1s — and delayed gastric emptying is pushing anesthesia/endoscopy toward standardized "hold-before-procedure" rules. Worth watching whether your shop adopts a hard stop vs. case-by-case. KFF GLP-1 use trends

Ideas & OpportunitiesSection E · actionable

Pre-empt the July 1 changeover. A 10-minute sync with inpatient pharmacy on (a) a GLP-1 hold/aspiration prompt and (b) surfacing the $50 Bridge pathway at discharge would get ahead of both the clinical and the "I can't afford it" headaches.

Off-shift watch: queue The Pitt S2, and if you want a palate cleanser, Hacks' final season is landing strong reviews — easy post-night-shift viewing.

Background / Already CoveredSection H · collapsed

Show items carried over or already reported

Guideline desk: no new SHM / IM / FM / USPSTF guideline in the last 48h. SHM's advocacy on the J-1 waiver backlog and the $100K H-1B fee for immigrant hospitalists (flagged June 19) still stands; the 2026 Surviving Sepsis Campaign update remains the live order-set item.
Golf: HackMotion's Sensor 4 wrist analyzer (orders shipping ~June 22) — already covered across the past week, nothing new.
Iran: the US–Iran 14-point MOU was formally signed in Switzerland and the conflict is being treated as ended (covered June 20). No fresh escalation — omitted from the top sections.
Florida insurance: the property-insurance rate-cap debate (SB30) and market-stabilization trend were covered June 20; no new development today.

Top StoriesSection A · confirmed fresh